ArticleMedicine2026
Rheumatoid arthritis and airway hyperresponsiveness: A GWAS-based mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous observational studies have indicated a link between rheumatoid arthritis (RA) and airway hyperresponsiveness diseases (AHDs). However, the causality of this relationship remains uncertain. Our research aims to investigate the causal relationship between RA and AHDs. Using publicly available genome-wide association study summary statistics, we selected single nucleotide polymorphisms associated with RA (including overall RA, seropositive RA and seronegative RA), and AHDs (including asthma, bronchitis, allergic rhinitis and chronic obstructive pulmonary disease [COPD]) as instrumental variables for 2-sample Mendelian randomization (MR) analysis. The primary analytical approach was the inverse variance weighted method. Other methods, such as weighted median, weighted mode, MR-Egger regression and MR pleiotropy residual sum and outlier, were employed for quality control. We also used multiple sensitivity analysis methods to verify the robustness of our result. Genetically determined RA (odds ratio [OR] = 1.007, 95% confidence interval [CI] = 1.003-1.011, P < .001), seropositive rheumatoid arthritis (OR = 1.007, 95% CI = 1.002-1.011, P = .037) had a causal effect with asthma, RA (OR = 1.001, 95% CI: 1.000-1.001, P = .022), seropositive rheumatoid arthritis (OR = 1.001, 95% CI: 1.000-1.001, P < .001), or seronegative rheumatoid arthritis (OR = 1.002, 95% CI: 1.001-1.003, P = .001) all were associated with bronchitis risk. No obvious causal relationship was found between RA and allergic rhinitis and COPD. Sensitivity analysis did not find obvious pleiotropy or heterogeneity. The results of this study showed that genetic susceptibility to RA was causally associated with an increased risk of asthma and bronchitis but not with allergic rhinitis and COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.